HomeProductsBioactive CompoundsEpigeneticsEpigenetic Reader DomainApabetalone
Chemical structure of CAS 1044870-39-4

Apabetalone

In Stock•Starting at $19 for 1 mg•Purity ≥ 99%
CAS No.1044870-39-4
MDL No.MFCD18633270
MFC20H22N2O5
MW370.40
InChI KeyNETXMUIMUZJUTB-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mg99%$19In Stock
5 mg99%$21In Stock
10 mg99%$25In Stock
50 mg99%$43In Stock
100 mg99%$70In Stock
250 mg99%$116In Stock
1 g99%$309In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1044870-39-4
Product NameApabetalone
Heavy Atom Count27Rotatable Bond Count6
Atom Stereo Count0Bond Stereo Count0
HBA6HBD2
TPSA93.670 ŲCharge0
Exact Mass370.15287Complexity1019.45
pKa7.130XLogP2.595

Related Articles

Studies related to this compound and its mechanism of action

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro.

Biomedicines • Vol. 9, Issue 4 • 2021
PMID: 33919584PMC: PMC8072876DOI: 10.3390/biomedicines9040437

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection.

Cell • Vol. 184, Issue 8 • 2021
PMID: 33811809PMC: PMC7962543DOI: 10.1016/j.cell.2021.03.026

The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation.

Acta pharmacologica Sinica • Vol. 40, Issue 1 • 2019
PMID: 29789664PMC: PMC6318340DOI: 10.1038/s41401-018-0027-5

A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.

Atherosclerosis • Vol. 236, Issue 1 • 2014
PMID: 25016363DOI: 10.1016/j.atherosclerosis.2014.06.008

Documentation

Similar Products